What’s New in Macrophage Activation Syndrome Therapeutics Save

Macrophage activation syndrome (MAS), the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.

The most robust evidence supports IFNγ blockade with emapalumab, now approved for MAS secondary to Still’s disease. In POS1045, pooled prospective trial data show that 53.8% of patients achieved complete response by week 8, with a median time to response of 16 days. Emapalumab is a monoclonal antibody that neutralizes both free and receptor-bound IFNγ, leading to rapid suppression of the IFNγ-driven inflammatory cascade. This was reflected by profound reductions in CXCL9 and ferritin. Complementary safety data demonstrate that higher drug exposure was not associated with increased infection or severe adverse events, reinforcing its tolerability. Together, these findings firmly establish emapalumab as a cornerstone targeted therapy in refractory MAS. Cost considerations and access issues do remain with the drug. 

Beyond IFNγ inhibition, emerging strategies aim to target upstream cytokines and broader immune pathways. A case report (POS0124) describes the use of MAS825, a bispecific IL-1β/IL-18 antibody, in a patient with refractory MAS after failure of IL-1 and IL-6 inhibitors. Treatment led to rapid clinical stabilization and sustained steroid-free remission over 18 months, suggesting that dual inflammasome cytokine blockade may overcome persistent hyperinflammation. However, this remains single-patient evidence, requiring validation in larger cohorts.

At the mechanistic level, POS0097 highlights IL-10 signaling as a central regulatory pathway in MAS. Single-cell RNA sequencing identified macrophage and monocyte subsets enriched for IL-10 receptor expression, and in a murine MAS model, albumin-fused IL-10 improved cytopenias and reduced IFNγ levels, outperforming IL-1 and IL-6 inhibition. These findings suggest that augmenting anti-inflammatory pathways may complement cytokine blockade, although current evidence is preclinical.

Taken together, these studies illustrate a rapidly evolving treatment landscape. While emapalumab anchors IFNγ-targeted therapy with strong clinical and safety data, emerging approaches—including dual IL-1/IL-18 blockade and IL-10 pathway augmentation—highlight a shift toward precision modulation of both pro-inflammatory and regulatory immune axes in MAS.